188 related articles for article (PubMed ID: 17704983)
1. [Management of capecitabine-induced hand-foot syndrome by local phytotherapy].
Kern E; Schmidinger M; Locker GJ; Kopp B
Wien Med Wochenschr; 2007; 157(13-14):337-42. PubMed ID: 17704983
[TBL] [Abstract][Full Text] [Related]
2. Topical henna for capecitabine induced hand-foot syndrome.
Yucel I; Guzin G
Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
[TBL] [Abstract][Full Text] [Related]
3. [Hand-foot syndrome with capecitabine therapy].
Marini A; Hengge UR
Hautarzt; 2007 Jun; 58(6):532-6. PubMed ID: 16897045
[TBL] [Abstract][Full Text] [Related]
4. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
[TBL] [Abstract][Full Text] [Related]
5. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma.
Goyal R; Chalamalasetty SB; Madan K; Paul SB; Arora R; Safaya R; Acharya SK
Indian J Gastroenterol; 2007; 26(6):292-3. PubMed ID: 18431015
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine and hand-foot syndrome.
Saif MW
Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
[TBL] [Abstract][Full Text] [Related]
7. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Do JE; Kim YC
Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
[TBL] [Abstract][Full Text] [Related]
9. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Son HS; Lee WY; Lee WS; Yun SH; Chun HK
Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
[TBL] [Abstract][Full Text] [Related]
10. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS
Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027
[TBL] [Abstract][Full Text] [Related]
11. [A woman with palmar and plantar hyperpigmentation].
van Tienhoven G; Wilmink JW
Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
Tavares-Bello R
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1434-5. PubMed ID: 17958867
[No Abstract] [Full Text] [Related]
13. High frequency of hand foot syndrome with capecitabine.
Kamil M; Haron M; Yosuff N; Khalid I; Azman N
J Coll Physicians Surg Pak; 2010 Jun; 20(6):421-2. PubMed ID: 20642979
[TBL] [Abstract][Full Text] [Related]
14. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
15. [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
Sauter C; Saborowski A; Ockenfels HM
Hautarzt; 2007 Jul; 58(7):619-22. PubMed ID: 17066280
[TBL] [Abstract][Full Text] [Related]
16. A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter.
Ciccolini J; Evrard A; Lacarelle B
Clin Cancer Res; 2012 Jan; 18(1):317. PubMed ID: 22215908
[No Abstract] [Full Text] [Related]
17. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
[TBL] [Abstract][Full Text] [Related]
18. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
Vickers MM; Easaw JC
J Gastrointest Cancer; 2008; 39(1-4):141-3. PubMed ID: 19440857
[TBL] [Abstract][Full Text] [Related]
19. Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
Latif S; Fraga G; Gadzia J
J Drugs Dermatol; 2010 Mar; 9(3):268-70. PubMed ID: 20232590
[TBL] [Abstract][Full Text] [Related]
20. Candidate mechanisms for capecitabine-related hand-foot syndrome.
Milano G; Etienne-Grimaldi MC; Mari M; Lassalle S; Formento JL; Francoual M; Lacour JP; Hofman P
Br J Clin Pharmacol; 2008 Jul; 66(1):88-95. PubMed ID: 18341672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
